Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients

被引:92
作者
He, Zi-Li [1 ]
Zheng, He [1 ]
Lin, Hui [1 ]
Miao, Xiong-Ying [1 ]
Zhong, De-Wu [1 ]
机构
[1] Cent S Univ, Dept Hepatobiliary Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China
关键词
Hepatocellular carcinoma; Immunohistochemistry; Reverse transcription-polymerase chain reaction; Survival analysis; Polo-like kinase 1; POLO-LIKE-KINASE-1; PLK1; BREAST-CANCER; CHROMOSOMAL INSTABILITY; PANCREATIC-CANCER; HIGH EXPRESSION; GASTRIC-CANCER; EARLY EVENT; CELL-CYCLE; IDENTIFICATION; APOPTOSIS;
D O I
10.3748/wjg.15.4177
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
AIM: To elucidate the role of overexpressed polo-like kinase1 (PLK1) in hepatocellular carcinoma (HCC). METHODS: We prospectively collected clinicopathological, immunohistochemical and semi-quantitative reverse transcription-polymerase chain reaction (RTPCR) data from 135 HCC patients undergoing successful hepatectomy. The correlations between PLK1 mRNA expression and clinicopathologic variables were analyzed by Mann-Whitney U test. Prognostic factors were identified by univariate and multivariate analyses. RESULTS: Immunohistochemical results showed overexpression of PLK1 was mainly found in tumor tissues compared with tumor-free tissue. A similar mRNA result was obtained by semi-quantitative RT-PCR. A total of Ill samples were positive for PLK1 mRNA expression. The positive expression was correlated With venous invasion, tumor nodules and Edmondson grade. Furthermore, 1, 3, 5-year survival rates in the positive expression group were significantly lower than the negative control group. Multivariate analysis showed that positive PLK1 expression was an independent risk factor for HCC. CONCLUSION: PLK1 could be a potential biomarker for diagnosis and therapy for HCC. (C) 2009 The WIG Press and Baishideng. All rights reserved.
引用
收藏
页码:4177 / 4182
页数:6
相关论文
共 45 条
[1]
Belghiti Jacques, 2005, HPB (Oxford), V7, P42, DOI 10.1080/13651820410024067
[2]
Molecular viral oncology of hepatocellular carcinoma [J].
Block, TM ;
Mehta, AS ;
Fimmel, CJ ;
Jordan, R .
ONCOGENE, 2003, 22 (33) :5093-5107
[3]
Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells [J].
Bu, Youquan ;
Yang, Zhengmei ;
Li, Quanhai ;
Song, Fangzhou .
ONCOLOGY, 2008, 74 (3-4) :198-206
[4]
Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells [J].
Chen, Xue-Hua ;
Lan, Bin ;
Qu, Ying ;
Zhang, Xiao-Qing ;
Cai, Qu ;
Liu, Bing-Ya ;
Zhu, Zheng-Gang .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (01) :29-35
[5]
Increased human polo-like kinase-1 expression in gliomas [J].
Dietzmann, K ;
Kirches, E ;
von Bossanyi, P ;
Jachau, K ;
Mawrin, C .
JOURNAL OF NEURO-ONCOLOGY, 2001, 53 (01) :1-11
[6]
Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma [J].
Feng, Yan-Bin ;
Lin, De-Chen ;
Shi, Zhi-Zhou ;
Wang, Xiao-Chun ;
Shen, Xiao-Ming ;
Zhang, Yu ;
Du, Xiao-Li ;
Luo, Man-Li ;
Xu, Xin ;
Han, Ya-Ling ;
Cai, Yan ;
Zhang, Zi-Qiang ;
Zhan, Qi-Min ;
Wang, Ming-Rong .
INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (03) :578-588
[7]
Gray PJ, 2004, MOL CANCER THER, V3, P641
[8]
Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma [J].
Ito, Y ;
Miyoshi, E ;
Sasaki, N ;
Kakudo, K ;
Yoshida, H ;
Tomoda, C ;
Uruno, T ;
Takamura, Y ;
Miya, A ;
Kobayashi, K ;
Matsuzuka, F ;
Matsuura, N ;
Kuma, K ;
Miyauchi, A .
BRITISH JOURNAL OF CANCER, 2004, 90 (02) :414-418
[9]
Active cyclin B1-Cdk1 first appears on centrosomes in prophase [J].
Jackman, M ;
Lindon, C ;
Nigg, EA ;
Pines, J .
NATURE CELL BIOLOGY, 2003, 5 (02) :143-148
[10]
Jang YJ, 2006, INT J ONCOL, V29, P589